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Background: Pathological studies have revealed atherosclerotic neointima (AN) after stent implantation. However, the risk factor of neoatherosclerosis and its impact on future clinical events remain unclear. Methods: From the Kobe university OCT database, 137 consecutive patients (253 stents) who underwent OCT examination at >1 year after bare metal or first-generation drug-eluting stent implantation were enrolled. We assessed AN (neointima containing a diffuse border, signal-poor region with invisible struts underneath) by follow-up OCT and compared major adverse cardiovascular event (MACE: death, recurrent myocardial infarction and target lesion revascularization (TLR)) rate between +AN and -AN group. Results: 38 patients had AN at follow-up OCT, who had higher LDL-cholesterol and high sensitivity CRP (hs-CRP) level. In multivariate logistic analysis, LDL cholesterol and hs-CRP were the independent predictors of the presence of AN (OR 1.025 (P¼0.011), OR 1.016 (P¼0.045), respectively). The rate of MACE were significantly higher in +AN than in -AN for an average follow-up of 58 months after stenting. After multivariate cox hazard analysis, the presence of AN remained an independent risk factor of MACE (HR 2.345, 95% CI 1. 010-5.440, P¼0.047) .
Conclusions: Increased LDL-cholesterol and hs-CRP level may be risk factors for AN progression in patients treated with coronary stents. In this study, the presence of AN assessed by OCT were independently associated with MACE at >1 year after stent placement, suggesting a need for careful clinical follow-up of patients with AN.
TCT-457
Is Background: The clinical presentation of bare metal in-stent restenosis (ISR) is reported to be associated with high rates of morbidity, including myocardial infarction (MI). This study aimed to compare the clinical presentation and outcomes between patients treated with 1st-versus 2nd-generation drug-eluting stents (DES) and presented with ISR on admission. Methods: The study identified first episode 1st or 2nd-generation DES ISR patients who underwent re-intervention. The clinical presentation at admission was classified as non acute (asymptomatic or stable angina) or acute (unstable angina, Canadian Cardiovascular Society (CCS) III or IV and MI). We compared the 1st-vs. 2nd-gen DES ISR clinical presentation and the rates of major adverse cardiac events (MACE) as a composite of death, Q-wave MI and target lesion revascularization at 6 months. Results: Overall, 709 patients with 1095 DES ISR lesions (1st-gen DES n¼526; 2ndgen DES n¼113) were selected. The mean age was 65 AE 10 years and diabetics comprised 49%. Clinical presentation included asymptomatic/stable angina in 29%, unstable angina in 62% and MI in 8%. Patients with 2nd-generation DES ISR were less likely to present as MI(13% vs. 5%; p¼0.05) and with severe symptoms (73% vs. 49%, p<0.01) as compared to 1st-gen DES. The incidence of MACE in the 1st-and 2nd-gen DES at 6 months was 8% and 9%, respectively (p¼1.0). Conclusions: 2nd-generation DES ISR clinical presentation appears to be more benign with less frequency of MI and CCS III or IV symptoms compared to 1stgeneration DES. The rates of MACE were similar at 6 months.
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Angiographic localized haziness after drug-coated balloon angioplasty in de-novo lesions does not increase the risk of acute coronary thrombosis Theresa Weichert 1 , Annette Fengler 1 , Philip Steen 1 , Klaus Bonaventura 1 1
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Background: Clinical studies demonstrated the effectiveness and safety of drug-coated balloon (DCB) in various clinical scenarios and support the use of paclitaxel-coated balloon for the treatment of in-stent restenosis, of small coronary arteries and bifurcation lesions. A few small scale studies have reported excellent immediate and short term results of DCB use compared to non-coated balloon for de-novo lesions. Initial angiographic Background: Clinical studies demonstrated the safety and effectiveness of drugcoated balloon (DCB) in various clinical scenarios and support the use of paclitaxeleluting balloon for the treatment of in-stent restenosis, of small coronary arteries and bifurcation lesions. We analyzed and compared the safety, focused on the rates of late coronary thrombosis (LT), after DCB in de-novo lesions without additional stentingthe so called "Drug-eluting balloon only" strategy -in four current studies with the outcome in a clinical setting. Conclusions: The use of DCB in de-novo coronary artery disease is not associated with a higher rate of LT. Beside the proven efficacy the possible reduction in the duration of DAPT to one month may represent additional advantages regarding safety, patient compliance and costs for the Drug-eluting balloon only strategy. Further larger scale studies are needed before DCB can be recommended for routine initial use in all cases as an alternative approach. Background: In-stent restenosis (ISR) remains as a limitation of percutaneous coronary intervention (PCI). Post-implantation stent expansion assessed by intravascular ultrasound (IVUS) has been used to optimize PCI outcomes, but there are limited data regarding on the effect of local stent expansion on ISR. The objective of this study was to assess the relationship between local stent expansion and in-stent hyperplasia (ISH) and lumen loss. Methods: Vascular profiling (3-vessel 3D coronary reconstruction by angiography & IVUS) was performed in 374 patients at baseline (BL) & 6-10 months follow-up (FU). Each reconstructed coronary artery was divided into 1.5-mm segments for serial study. A total of 80 bare-metal stents (BMS), 51 sirolimus-eluting stents (SES) and 25 paclitaxel-eluting stents (PES) were analyzed. At baseline, local stent expansion was defined as the ratio of stent area to the respective reference lumen area. Stent expansion ratio was categorized as underexpansion (stent expansion <0.8), normal (stent expansion 0.8-1.2) and overexpansion (stent expansion > 1.2).
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Magnitude of Stent Expansion Influences Local In-Stent Hyperplasia and Lumen Changes Following Stent Implantation in Humans
Results: ISH area in overexpansion group is significantly larger than in underexpansion group at FU (3.3 AE 2.0 mm2 vs 2.0 AE 1.4 mm2, p<0.001 in BMS; 0.33 AE 0.53 mm2 vs 0.0036 AE 0.028 mm2, p<0.001 in SES; and 0.71 AE 0.78 mm2 vs 0.44 AE 0.42 mm2, p¼0.014 in PES). There was significant lumen area decrease in overexpansion group at FU compared to underexpansion group in all stent types (delta¼ 3.3 AE 2.0 mm2 vs 0.61 AE 2.3 mm2, p<0.001 in BMS; delta¼ 0.55 AE 1.5 mm2 vs -1.7 AE 1.6 mm2, p<0.001 in SES; and delta¼ 1.2 AE 1.2 mm2 vs -0.52 AE 1.1 mm2, p<0.001 in PES). Lumen area in overexpansion group in SES became smaller than in underexpansion group (8.1 AE 1.5 mm2 vs 9.2 AE 3.0 mm2, p¼0.01 in SES). In BMS and PES, the relationship in lumen area at FU between overexpansion and underexpansion groups were similar (8.7 AE 2.5 mm2 vs 9.0 AE 4.6 mm2, p¼0.58 in BMS; 8.1 AE 1.2 mm2 vs 7.7 AE 1.8 mm2, p¼0.12 in PES).
Conclusions: Overexpanded stent segment showed greater ISH and lumen loss at FU regardless of stent type. There is less advantage of aggressive dilation at stent deployment to get larger lumen.
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Isolated Background: It was reported that peri-stent contrast staining (PSS) was one of abnormal vessel reactions including incomplete stent apposition assessed with optical coherence tomography. Little is known about the differences in temporal change of PSS among various stents. Methods: Between October 2001 and February 2012, percutaneous coronary intervention was performed with bare-metal stent (BMS) in 2138 lesions and with drugeluting stent (DES) in 11138 lesions. We routinely performed follow-up coronary angiography (CAG) at 6th and 18th month after BMS implantation and 8th and 20th month after DES implantation, and found PSS in 56 lesions with BMS and 281 lesions with DES (2.62% vs. 2.52%, p¼0.764). The temporal change of PSS between 6-8 and 18-20 months after stent implantation was confirmed with CAG in 36 lesions with BMS and 191 lesions with DES, which were classified into 3 groups: progressive, unchanged, and regressive PSS. We examined the difference in temporal change of PSS between DES and BMS. Furthermore, the temporal change after the 20th month of stent implantation was examined with unscheduled CAG in 9 BMS lesions and 53 DES lesions. DES were classified into SES and non-SES. Results: The results are shown in the figure. Progressive PSS after 20th month of stent implantation was observed only in 9 of 43 lesions (20.9%) after SES implantation.
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